Not all nasal samples are created equal. Where and how we collect pathogen-containing material for upper respiratory infection (URI) testing can make all the difference between a confirmed infection and a missed case.
The crux of a “good” versus “bad” sample? Its sensitivity, or ability to identify the pathogen causing a URI. Low sensitivity — often seen with nasal swab samples — can lead to higher rates of false negatives, delaying medication intervention and potentially exposing others to the virus. In high-risk patients (i.e., people 65 and older, 5 and under or with a chronic disease), timeliness is critical for preventing hospitalization and/or death.
Evolved nasal lavage addresses these issues head-on, delivering 11% to 49% greater sensitivity compared to nasal swabs. Dive into how this solution outperforms swabs and why it matters, from anatomical differences to the amount of pathogen-containing material captured.
Why Was Nasal Swab Testing the COVID-19 Default?
When COVID-19 strained healthcare systems worldwide, speed to testing took priority as nasopharyngeal swabs emerged as the default for URI specimen collection. It wasn’t the most evidence-backed method, but it was the only option that could keep pace with extraordinary demand.
Existing supply chains, manufacturing capacity and provider familiarity allowed swabs to be distributed and deployed more rapidly than other solutions, such as nasal lavage. Nasal lavage sampling demonstrated better reliability and sensitivity in clinical and research settings decades before the pandemic, but it was messy, unstandardized, placed healthcare professionals at a much greater risk for infection, and wasn’t practical to roll out on a global scale. Therefore, swabs filled the vacuum by default.
However, the drawbacks of nasal swab testing quickly came to light. Swab specimen adequacy is heavily dependent on healthcare providers properly administering the procedure and patient cooperation, and an inadequate sample can lead to delays in diagnoses and treatment. Add in significant discomfort for patients, and it’s no wonder testing avoidance skyrocketed.
Discomfort & Injuries from Swabs Cause Avoidance, Accelerating the Spread
At the peak of pandemic specimen collection, complaints about the nasal swab were quite common among patients. Nasal swab sampling requires deep insertion into the nose — typically 4 to 6 inches — provoking involuntary reactions like flinching, sneezing, gagging, coughing eye-watering or nosebleeds. Consequently, swab avoidance and fatigue surged:
- In a 2020 survey of 2,000 U.S. adults, 34% reported comfort was the single most important factor when choosing a specimen collection method.
- More recently, JAMA reports nearly a third of Americans would not, or might not, test for suspected COVID-19 with the swab as of June 2025.
Discomfort isn’t the only concern — nasal swabs can also lead to rare yet serious complications. A 2022 study in the American Journal of Rhinology & Allergy revealed issues like retained foreign bodies and nosebleeds occurred in roughly one out of every 600 cases. While that ratio may appear small, 363 million samples were collected during the pandemic. That means nearly half a million people experienced harmful outcomes due to nasal swabs.
This undermines two of our most important tools in slowing viral spread: early case identification and isolation. Avoidance and fear of injury increase the likelihood of missed or delayed diagnoses, as well as treatment falling outside the ideal clinical windows for oral antiviral medications, when appropriate.
The key to improving participation and compliance, according to clinical experts? Adapting specimen collection methods to become both clinically effective and patient-friendly.
The Result: Fewer People Tested, More Risks of Spread
Reduced testing volume makes it harder to accurately track disease spread, delaying interventions as outbreaks escalate unchecked. And even when patients do choose to get tested:
- Nasal swab administration techniques are highly subjective to the user, especially when self-administered. Lower-quality specimens result in less reliable diagnoses.
- Nasal swabs coupled with antigen tests have low sensitivity; just 38% in asymptomatic individuals and 64.2% in symptomatic individuals, according to the Centers for Disease Control (CDC).
- False negatives are a frequent occurrence among nasal swab antigen tests, with the CDC reporting false negative rates averaging 30% to 50% during the first three to five days of symptom onset.
Ultimately, testing avoidance and its downstream effects compromise our effective management and containment of both seasonal and emerging URIs.
Evolved Nasal Lavage Improves the Patient Experience
As general, widespread testing fatigue sets in and the immediate pressures of pandemic-era protocols subside, public health and infectious disease specialists are beginning to take a closer look at entrenched practices for URI specimen collection. Attention has now turned toward approaches that ease the burden on patients while raising the bar for diagnostic accuracy.
Within this transition, evolved nasal lavage has surfaced as a patient-focused option that also delivers stronger results for providers and laboratories.
Instead of requiring deep penetration into the nose, the method uses a gentle saline rinse to wash the full nasal passage, capturing epithelial cells along with causative microscopic pathogens. Nasal lavage sampling produces a liquid sample that is more easily reproducible and consistent compared to other collection techniques (e.g., nasal swabs) and offers a far more tolerable experience for patients across age groups and backgrounds.
The advantages are significant:
- Virtually eliminates patient pain, trauma, injury and adverse reactions.
- Reduces fears and anxieties surrounding specimen collection to reduce test avoidance.
- Simplifies and standardizes sample collection for healthcare personnel, especially in pediatrics and geriatrics.
- Produces higher-sensitivity samples and seamless integration into existing workflows for labs.
As healthcare organizations refine their diagnostic approaches, evolved nasal lavage has set a new benchmark for safer, more sensitive specimen collection — enabling faster, more precise diagnoses and stronger control of viral spread.
Reassessing Our Testing Approach Beyond the Tools
It’s important to note that tackling testing avoidance takes more than simply swapping out our preferred devices. Educating patients plays a crucial role. When people are aware of less-invasive options that produce a higher-sensitivity sample, their willingness to participate grows.
Equally important is open communication from healthcare providers. Setting clear expectations about the process — including potential risks, advantages and available alternatives — helps boost trust and compliance.
At the policy level, decision-makers should champion sampling techniques that balance comfort, diagnostic sensitivity and scalability. With the right approach, healthcare systems don’t have to choose between patient satisfaction and building a stronger, more effective diagnostic framework.
MicroWash: Evolved Specimen Collection Built for Timely & Effective Outbreak Response
COVID-19 revealed just how much collection techniques directly influence whether patients choose to get tested. As care models shift from crisis response to long-term preparedness, methods that emphasize safety, sensitivity and comfort will define the path to progress.
At the forefront of this new era of testing is MicroWash. This nasal lavage specimen collection device surpasses the swab on virtually all levels, from patient comfort to provider ease of use and lab testing accuracy.
MicroWash yields up to 49% greater sample sensitivity than the swab despite being significantly less invasive, changing people’s attitudes toward testing to support global health outcomes.
Discover more advantages of MicroWash over nasal swabs and contact our medical experts to equip your healthcare environment with the future of URI sampling.
Interested in exploring the science further? View our Supporting Research Guide.
